NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

Moderna logo
$215.27 -8.10 (-3.63%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$213.58 -1.69 (-0.78%)
As of 04:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Moderna Stock (NASDAQ:MRNA)

Advanced

Key Stats

Today's Range
$212.50
▼
$220.59
50-Day Range
$135.61
▼
$269.00
52-Week Range
$22.28
▼
$280.80
Volume
7.00 million shs
Average Volume
15.52 million shs
Market Capitalization
$87.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$113.75
Consensus Rating
Hold

Company Overview

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts. Its products and development programs serve markets in the United States and internationally.

AI Generated. May Contain Errors.

Moderna Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

MRNA MarketRank™: 
1.398745997865 of 5 stars

Moderna scored higher than 28% of companies evaluated by MarketBeat, and ranked 783rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Moderna has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 6 buy ratings, 15 hold ratings, and 4 sell ratings.

  • Downside Risk

    Moderna has a consensus price target of $113.75, representing about 47.2% downside from its current price of $215.27.

  • Amount of Analyst Coverage

    Moderna has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Moderna's stock forecast and price target.
  • Earnings Growth

    Earnings for Moderna are expected to grow in the coming year, from ($5.14) to ($3.69) per share.

  • Price to Book Value per Share Ratio

    Moderna has a P/B Ratio of 12.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.32% of the float of Moderna has been sold short.
  • Short Interest Ratio / Days to Cover

    Moderna has a short interest ratio ("days to cover") of 1.76, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Moderna has recently increased by 1.80%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Moderna does not currently pay a dividend.

  • Dividend Growth

    Moderna does not have a long track record of dividend growth.

  • News Sentiment

    Moderna has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 48 news articles for Moderna this week, compared to 9 articles on an average week.
  • Search Interest

    Only 65 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • MarketBeat Follows

    Only 26 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,875,904.00 in company stock.

  • Percentage Held by Insiders

    10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Moderna's insider trading history.
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRNA Stock News Headlines

A Nasdaq drone company just landed a deal with a Philippine billionaire's group
A Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue. The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more. It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines.tc pixel
Moderna, Inc. (MRNA) - What Are Analysts Saying About This Stock?
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom (MRNA)
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology...
Vaccine vial and syringe on a lab surface with DNA strands and virus particle illustrations in the background.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Vaccine vial and syringe on a lab surface with DNA strands and virus particle illustrations in the background.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning (MRNA)
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
See More Headlines

MRNA Stock Analysis - Frequently Asked Questions

Moderna's stock was trading at $29.49 at the beginning of the year. Since then, MRNA shares have increased by 630.0% and is now trading at $215.27.

Moderna, Inc. (NASDAQ:MRNA) announced its earnings results on Friday, November, 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $1.48. The business's quarterly revenue was up 29.2% compared to the same quarter last year.
Read the conference call transcript
.

Moderna (MRNA) raised $604 million in an IPO on Friday, December 7th 2018. The company issued 26,275,993 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Top institutional shareholders of Moderna include State Street Corp (3.82%), Theleme Partners LLP (1.65%), Banque Pictet & Cie SA (0.54%) and Douglas Lane & Associates LLC (0.29%). Insiders that own company stock include Stephen Hoge, Shannon Thyme Klinger, James M Mock, Abbas Hussain, Noubar Afeyan and Arpa Garay.
View institutional ownership trends
.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), NIO (NIO), Alibaba Group (BABA) and PayPal (PYPL).

Company Calendar

Last Earnings
11/06/2026
Today
11/17/2026
Jefferies Global Healthcare Conference
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MRNA
CIK
1682852
Fax
N/A
Employees
4,700
Year Founded
2010

Price Target and Rating

High Price Target
$305.00
Low Price Target
$17.00
Potential Upside/Downside
-47.2%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
($7.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.82 billion
Net Margins
-110.46%
Pretax Margin
-108.08%
Return on Equity
-25.79%
Return on Assets
-15.85%

Debt

Debt-to-Equity Ratio
0.52
Current Ratio
3.62
Quick Ratio
3.47

Sales & Book Value

Annual Sales
$1.94 billion
Price / Sales
44.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.90 per share
Price / Book
12.74

Miscellaneous

Outstanding Shares
404,620,000
Free Float
360,922,000
Market Cap
$87.10 billion
Optionable
Optionable
Beta
1.16

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:MRNA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners